Clinical & Experimental Cardiology
Open Access

Shinsuke Mori

Publications

• Research Article
  Efficacy And Safety of Coadministration of Tolvaptan And Carperitide for Acute Decompensated Heart Failure Patients
  Author(s): Hideyuki Takimura, Toshiya Muramatsu, Yoshiaki Ito, Tsuyoshi Sakai, Keisuke Hirano, Masahiro Yamawaki, Motoharu Araki, Norihiro Kobayashi, Yasunari Sakamoto, Shinsuke Mori, Masakazu Tsutsumi, Takuro Takama, Hiroya Takafuji, Yosuke Honda, Takahiro Tokuda and Kenji Makino Hideyuki Takimura, Toshiya Muramatsu, Yoshiaki Ito, Tsuyoshi Sakai, Keisuke Hirano, Masahiro Yamawaki, Motoharu Araki, Norihiro Kobayashi, Yasunari Sakamoto, Shinsuke Mori, Masakazu Tsutsumi, Takuro Takama, Hiroya Takafuji, Yosuke Honda, Takahiro Tokuda and Kenji Makino
  
  For acute decompensated heart failure (ADHF) therapy, combination of carperitide, a human atrial natriuretic peptide, and tolvaptan, a novel vasopressin type 2 receptor antagonists, has not been used. Tolvaptan is a drug newly developed to treat volume overload in ADHF patients. Of 102 consecutive cases treated upon admission for ADHF between April and October 2012, we analyzed 51 patients treated with carperitide plus tolvaptan (tolvaptan+carperitide group) and 51 patients treated with carperitide plus conventional diuretics (carperitide group). On comparison between both groups, total dose of carperitide and loop diuretic doses during 48 h in tolvaptan +carperitide group were lower than those in the carperitide group (both p<0.001). Urine output at 24 h and 48 h after admission in the tolvaptan+carperitide group were significantly higher than those in carperitide group (p=0.02 an.. View More»
  DOI: 10.4172/2155-9880.1000395

  Abstract PDF

Relevant Topics